NCT02381548 2026-01-30
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
Clinical Trials
8 trialsNCT04197713 2025-10-20
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04460937 2025-07-08
Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT01849146 2025-01-09
Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT03345784 2024-02-20
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01922076 2024-01-31
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
National Cancer Institute (NCI)
Phase 1 Completed
NCT01748825 2021-07-26
AZD1775 for Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02791919 2017-05-03
Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Withdrawn